H. Res. __

H.R. 6 - 21st Century Cures Act

1. Structured rule.
2. Provides one hour of general debate equally divided and controlled by the chair and ranking minority member of the Committee on Energy and Commerce.
3. Waives all points of order against consideration of the bill.
4. Provides that an amendment in the nature of a substitute consisting of the text of Rules Committee Print 114-22 shall be considered as adopted and the bill, as amended, shall be considered as read.
5. Waives all points of order against provisions in the bill, as amended.
6. Makes in order only those further amendments printed in the Rules Committee report. Each such amendment may be offered only in the order printed in the report, may be offered only by a Member designated in the report, shall be considered as read, shall be debatable for the time specified in the report equally divided and controlled by the proponent and an opponent, shall not be subject to amendment, and shall not be subject to a demand for division of the question.
7. Waives all points of order against the amendments printed in the report.
8. Provides one motion to recommit with or without instructions.

RESOLUTION

Resolved, That at any time after adoption of this resolution the Speaker may, pursuant to clause 2(b) of rule XVIII, declare the House resolved into the Committee of the Whole House on the state of the Union for consideration of the bill (H.R. 6) to accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. The first reading of the bill shall be dispensed with. All points of order against consideration of the bill are waived.
General debate shall be confined to the bill and amendments specified in this resolution and shall not exceed one hour equally divided and controlled by the chair and ranking minority member of the Committee on Energy and Commerce. After general debate the bill shall be considered for amendment under the five-minute rule. In lieu of the amendment in the nature of a substitute recommended by the Committee on Energy and Commerce now printed in the bill, an amendment in the nature of a substitute consisting of the text of Rules Committee Print 114-22 shall be considered as adopted in the House and in the Committee of the Whole. The bill, as amended, shall be considered as the original bill for the purpose of further amendment under the five-minute rule and shall be considered as read. All points of order against provisions in the bill, as amended, are waived. No further amendment to the bill, as amended, shall be in order except those printed in the report of the Committee on Rules accompanying this resolution. Each such further amendment may be offered only in the order printed in the report, may be offered only by a Member designated in the report, shall be considered as read, shall be debatable for the time specified in the report equally divided and controlled by the proponent and an opponent, shall not be subject to amendment, and shall not be subject to a demand for division of the question in the House or in the Committee of the Whole. All points of order against such further amendments are waived. At the conclusion of consideration of the bill for amendment the Committee shall rise and report the bill, as amended, to the House with such further amendments as may have been adopted. The previous question shall be considered as ordered on the bill, as amended, and on any further amendment thereto, to final passage without intervening motion except one motion to recommit with or without instructions.

**SUMMARY OF AMENDMENTS PROPOSED TO BE MADE IN ORDER**

*(summaries derived from information provided by sponsors)*

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Description</th>
<th>Debate Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Brat (VA), McClintock (CA), Garrett (NJ), Stutzman (IN), Perry (PA)</td>
<td>#29 Reforms the NIH and Cures Innovation Fund to make it a discretionary spending program.</td>
<td>(10 minutes)</td>
</tr>
<tr>
<td>2. Young (IN), Harris</td>
<td>#13 <em>(REVISED)</em> Creates authority within NIH to conduct a prize program. The intent of the program would be to</td>
<td>(10 minutes)</td>
</tr>
</tbody>
</table>
incentivize health innovation by offering competitors the chance to win a prize for creating breakthrough research and technology.

3. Lee, Barbara (CA), Schakowsky (IL), Clarke (NY)
   #11 Strikes the provision that applies any policy riders included in the annual LHHS Appropriations Bill to NIH funds in H.R. 6. Also strikes the provision that applies any policy riders applied to the FDA in the annual Agriculture Appropriations bill to FDA funding in H.R. 6.

4. Castro (TX)
   #19 Ensures underrepresented individuals, such as women and minorities, are included in the Supporting Young Emerging Scientists Report.

5. Slaughter (NY)
   #21 (REVISED) Directs the CDC to conduct a study to determine how the additional payments are affecting the development of drug resistance.

6. Fitzpatrick (PA)
   #8 Expresses a sense of Congress that recording Unique Device Identifiers at the point-of-care in electronic health record systems could significantly enhance the availability of medical device data for post-market surveillance purposes.

7. Polis (CO)
   #35 (LATE) (REVISED) Directs the Food and Drug Administration to issue a report on the risks and benefits associated with a two-tiered approval process that would permit certain medical devices to provisionally come to market if they have demonstrated safety but not efficacy.

8. Jackson Lee (TX)
   #15 Directs the Secretary of Health and Human Services to conduct outreach to Historically Black Colleges and Universities; Hispanic Serving Institutions; Native American Colleges; and rural Colleges to ensure that health professionals from underrepresented populations are aware of research opportunities under this Act.